IN8bio to Present at Cantor Oncology & HemOnc Conference
September 27 2022 - 6:30AM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical
company discovering and developing innovative gamma-delta T cell
therapies that utilize its DeltEx platform, today announced that
William Ho, IN8bio’s Chief Executive Officer, will be a speaker on
the “Cell Therapy in Solid Tumors” panel at the Cantor Oncology
& HemOnc Conference. The panel will take place at 1:45 p.m. ET
on September 28, 2022.
About IN8bioIN8bio is a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing gamma-delta T cell product
candidates for solid and liquid tumors. Gamma-delta T cells are a
specialized population of T cells that possess unique properties,
including the ability to differentiate between healthy and diseased
tissue. IN8bio’s DeltEx platform employs allogeneic, autologous,
iPSC, and genetically modified approaches to develop cell therapies
that synergize with chemotherapy to effectively identify and
eradicate tumor cells.
IN8bio is currently conducting two
investigator-initiated Phase 1 clinical trials for its lead
gamma-delta T cell product candidates: INB-200 for the treatment of
newly diagnosed glioblastoma and INB-100 for the treatment of
patients with leukemia undergoing hematopoietic stem cell
transplantation. IN8bio also has a broad portfolio of preclinical
programs focused on addressing other solid tumor types. For more
information about IN8bio and its programs, please
visit www.IN8bio.com.
Company Contact:IN8bio,
Inc.Patrick McCall+ 1 646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact:
Argot PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Sep 2024 to Oct 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Oct 2023 to Oct 2024